 Andres Henao Martinez
Concepts (492)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chagas Disease | 13 | 2023 | 38 | 7.140 |
Why?
| | Chagas Cardiomyopathy | 7 | 2023 | 22 | 4.330 |
Why?
| | Meningitis, Cryptococcal | 8 | 2024 | 30 | 3.630 |
Why?
| | Cryptococcosis | 6 | 2023 | 26 | 3.390 |
Why?
| | Opportunistic Infections | 4 | 2024 | 46 | 2.590 |
Why?
| | Trypanosoma cruzi | 6 | 2023 | 25 | 2.390 |
Why?
| | Cryptococcus neoformans | 4 | 2024 | 19 | 1.840 |
Why?
| | Invasive Pulmonary Aspergillosis | 2 | 2023 | 6 | 1.690 |
Why?
| | HIV Infections | 10 | 2024 | 2729 | 1.630 |
Why?
| | Travel | 6 | 2021 | 122 | 1.600 |
Why?
| | Strongyloidiasis | 2 | 2024 | 4 | 1.410 |
Why?
| | Cryptococcus | 2 | 2024 | 8 | 1.410 |
Why?
| | Immunocompromised Host | 6 | 2024 | 199 | 1.320 |
Why?
| | Stroke, Lacunar | 2 | 2019 | 4 | 1.250 |
Why?
| | Anti-Bacterial Agents | 9 | 2025 | 1708 | 1.180 |
Why?
| | Tuberculosis | 2 | 2022 | 273 | 1.160 |
Why?
| | Transients and Migrants | 3 | 2023 | 26 | 1.150 |
Why?
| | Humans | 104 | 2025 | 129527 | 1.140 |
Why?
| | Candidemia | 2 | 2024 | 10 | 1.140 |
Why?
| | Hospitalization | 7 | 2024 | 2076 | 1.110 |
Why?
| | Cardiomyopathies | 2 | 2021 | 339 | 1.080 |
Why?
| | Yellow Fever | 3 | 2022 | 7 | 1.060 |
Why?
| | Bacteremia | 5 | 2023 | 194 | 1.020 |
Why?
| | Infectious Disease Transmission, Vertical | 2 | 2019 | 171 | 1.000 |
Why?
| | Candida | 2 | 2024 | 37 | 0.970 |
Why?
| | Glucocorticoids | 3 | 2024 | 583 | 0.960 |
Why?
| | Antifungal Agents | 8 | 2023 | 130 | 0.960 |
Why?
| | Central Nervous System Neoplasms | 2 | 2018 | 149 | 0.940 |
Why?
| | Macrolides | 1 | 2025 | 60 | 0.910 |
Why?
| | Adult | 37 | 2025 | 35505 | 0.910 |
Why?
| | Parasitemia | 2 | 2015 | 11 | 0.900 |
Why?
| | Pneumocystis | 1 | 2024 | 11 | 0.890 |
Why?
| | Risk Factors | 15 | 2024 | 9779 | 0.880 |
Why?
| | Mycoses | 1 | 2024 | 73 | 0.880 |
Why?
| | Pneumonia, Pneumocystis | 1 | 2024 | 36 | 0.870 |
Why?
| | Drug Hypersensitivity | 1 | 2025 | 81 | 0.860 |
Why?
| | Pulmonary Aspergillosis | 1 | 2023 | 3 | 0.860 |
Why?
| | Nitroimidazoles | 1 | 2023 | 9 | 0.860 |
Why?
| | Pneumonia, Viral | 7 | 2020 | 342 | 0.840 |
Why?
| | Coronavirus Infections | 7 | 2020 | 336 | 0.830 |
Why?
| | Myocarditis | 2 | 2016 | 98 | 0.830 |
Why?
| | Anemia, Aplastic | 1 | 2023 | 36 | 0.830 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2024 | 123 | 0.810 |
Why?
| | Male | 45 | 2025 | 63586 | 0.800 |
Why?
| | Enterobacteriaceae Infections | 2 | 2013 | 41 | 0.790 |
Why?
| | Zoonoses | 2 | 2024 | 28 | 0.790 |
Why?
| | Virus Diseases | 1 | 2024 | 210 | 0.770 |
Why?
| | Antigens, Fungal | 2 | 2024 | 28 | 0.740 |
Why?
| | Immunotherapy, Adoptive | 1 | 2024 | 300 | 0.730 |
Why?
| | Neglected Diseases | 1 | 2020 | 4 | 0.710 |
Why?
| | Mycobacterium Infections | 2 | 2018 | 62 | 0.700 |
Why?
| | Hepatitis | 1 | 2020 | 47 | 0.690 |
Why?
| | Middle Aged | 24 | 2025 | 31087 | 0.670 |
Why?
| | Hantavirus Pulmonary Syndrome | 1 | 2020 | 3 | 0.670 |
Why?
| | Heart Aneurysm | 1 | 2019 | 10 | 0.660 |
Why?
| | Epidemics | 1 | 2020 | 82 | 0.640 |
Why?
| | Massive Hepatic Necrosis | 1 | 2019 | 3 | 0.640 |
Why?
| | United States | 19 | 2024 | 13865 | 0.630 |
Why?
| | Aneurysm, False | 1 | 2019 | 47 | 0.630 |
Why?
| | Hepatitis A | 1 | 2019 | 25 | 0.630 |
Why?
| | Leukemia, Myelomonocytic, Chronic | 1 | 2018 | 2 | 0.610 |
Why?
| | Neisseria gonorrhoeae | 1 | 2019 | 24 | 0.610 |
Why?
| | Sarcoma, Myeloid | 1 | 2018 | 4 | 0.610 |
Why?
| | Hematoma, Subdural | 1 | 2018 | 17 | 0.610 |
Why?
| | Female | 36 | 2025 | 68650 | 0.590 |
Why?
| | Plasmodium falciparum | 1 | 2018 | 30 | 0.580 |
Why?
| | Malaria, Falciparum | 1 | 2018 | 27 | 0.580 |
Why?
| | Skin | 3 | 2022 | 724 | 0.580 |
Why?
| | Gonorrhea | 1 | 2019 | 57 | 0.580 |
Why?
| | Fever | 2 | 2020 | 298 | 0.580 |
Why?
| | Chromoblastomycosis | 1 | 2017 | 1 | 0.580 |
Why?
| | Hand Dermatoses | 1 | 2017 | 7 | 0.570 |
Why?
| | Renal Insufficiency | 1 | 2020 | 149 | 0.570 |
Why?
| | Population Groups | 1 | 2018 | 60 | 0.570 |
Why?
| | Dyspnea | 1 | 2019 | 238 | 0.570 |
Why?
| | Delayed Diagnosis | 1 | 2018 | 79 | 0.560 |
Why?
| | Meningioma | 1 | 2018 | 82 | 0.560 |
Why?
| | Meningeal Neoplasms | 1 | 2018 | 94 | 0.560 |
Why?
| | Medically Uninsured | 1 | 2018 | 127 | 0.550 |
Why?
| | Abscess | 1 | 2018 | 73 | 0.550 |
Why?
| | Heart Failure | 2 | 2022 | 2143 | 0.540 |
Why?
| | Milk | 1 | 2018 | 122 | 0.540 |
Why?
| | Osteomyelitis | 1 | 2019 | 121 | 0.540 |
Why?
| | Pandemics | 10 | 2023 | 1500 | 0.530 |
Why?
| | Retrospective Studies | 12 | 2024 | 14532 | 0.530 |
Why?
| | Latin America | 6 | 2022 | 87 | 0.530 |
Why?
| | Poliomyelitis | 3 | 2022 | 36 | 0.520 |
Why?
| | Prisons | 4 | 2021 | 79 | 0.520 |
Why?
| | Trichuriasis | 1 | 2016 | 4 | 0.520 |
Why?
| | Pregnancy Complications, Parasitic | 1 | 2016 | 9 | 0.510 |
Why?
| | Lymphocytosis | 1 | 2016 | 10 | 0.510 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2016 | 13 | 0.510 |
Why?
| | Parotid Neoplasms | 1 | 2016 | 16 | 0.510 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2016 | 20 | 0.510 |
Why?
| | Enterobacteriaceae | 2 | 2013 | 39 | 0.510 |
Why?
| | Occupational Diseases | 1 | 2017 | 139 | 0.500 |
Why?
| | Diphyllobothriasis | 1 | 2015 | 2 | 0.500 |
Why?
| | Diphyllobothrium | 1 | 2015 | 2 | 0.500 |
Why?
| | Colombia | 4 | 2020 | 37 | 0.490 |
Why?
| | Plasmablastic Lymphoma | 1 | 2015 | 7 | 0.490 |
Why?
| | Insect Vectors | 1 | 2015 | 27 | 0.490 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2018 | 205 | 0.490 |
Why?
| | Gamma Rays | 1 | 2015 | 54 | 0.480 |
Why?
| | Plasma Cells | 1 | 2015 | 66 | 0.480 |
Why?
| | Transplants | 1 | 2015 | 35 | 0.480 |
Why?
| | Lymphoma | 1 | 2016 | 197 | 0.460 |
Why?
| | Anemia | 1 | 2016 | 161 | 0.460 |
Why?
| | Bone Marrow | 1 | 2016 | 272 | 0.450 |
Why?
| | Heart Ventricles | 1 | 2019 | 778 | 0.450 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2023 | 427 | 0.440 |
Why?
| | Thrombocytopenia | 1 | 2016 | 189 | 0.440 |
Why?
| | Environmental Exposure | 1 | 2018 | 463 | 0.430 |
Why?
| | Transplant Recipients | 1 | 2015 | 163 | 0.430 |
Why?
| | Aged | 12 | 2024 | 22063 | 0.420 |
Why?
| | Research | 1 | 2016 | 419 | 0.420 |
Why?
| | Myocardial Contraction | 1 | 2015 | 334 | 0.420 |
Why?
| | Betacoronavirus | 6 | 2020 | 252 | 0.410 |
Why?
| | Lymphoma, Primary Effusion | 1 | 2013 | 3 | 0.410 |
Why?
| | Thrombocytosis | 1 | 2013 | 6 | 0.410 |
Why?
| | Lymphoma, AIDS-Related | 1 | 2013 | 14 | 0.410 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 4 | 2023 | 221 | 0.400 |
Why?
| | Herpesvirus 8, Human | 1 | 2013 | 60 | 0.400 |
Why?
| | Antigens, Protozoan | 1 | 2012 | 22 | 0.390 |
Why?
| | Acinetobacter Infections | 1 | 2012 | 12 | 0.390 |
Why?
| | Acinetobacter | 1 | 2012 | 13 | 0.390 |
Why?
| | Proctitis | 1 | 2012 | 6 | 0.390 |
Why?
| | Herpes Genitalis | 1 | 2012 | 16 | 0.390 |
Why?
| | H-2 Antigens | 1 | 2012 | 115 | 0.390 |
Why?
| | Herpesvirus 2, Human | 1 | 2012 | 28 | 0.380 |
Why?
| | Cellulitis | 1 | 2012 | 49 | 0.380 |
Why?
| | Incidence | 3 | 2025 | 2643 | 0.380 |
Why?
| | Isoxazoles | 1 | 2012 | 54 | 0.380 |
Why?
| | Yellow Fever Vaccine | 2 | 2022 | 5 | 0.370 |
Why?
| | Severe Dengue | 1 | 2011 | 10 | 0.370 |
Why?
| | Acyclovir | 1 | 2012 | 99 | 0.370 |
Why?
| | Herpesviridae Infections | 1 | 2013 | 142 | 0.370 |
Why?
| | Healthcare Disparities | 3 | 2024 | 579 | 0.360 |
Why?
| | Emigration and Immigration | 2 | 2022 | 49 | 0.360 |
Why?
| | Animals | 15 | 2024 | 35334 | 0.360 |
Why?
| | Treatment Outcome | 11 | 2024 | 10232 | 0.350 |
Why?
| | B-Lymphocytes | 1 | 2016 | 816 | 0.350 |
Why?
| | Poliovirus | 2 | 2022 | 82 | 0.340 |
Why?
| | Pancreatitis | 1 | 2011 | 124 | 0.340 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3392 | 0.330 |
Why?
| | Acute Lung Injury | 1 | 2013 | 280 | 0.330 |
Why?
| | Moraxella | 1 | 2009 | 5 | 0.330 |
Why?
| | Moraxellaceae Infections | 1 | 2009 | 3 | 0.330 |
Why?
| | Repressor Proteins | 1 | 2013 | 404 | 0.320 |
Why?
| | Lung Diseases | 2 | 2018 | 741 | 0.320 |
Why?
| | Lupus Nephritis | 1 | 2009 | 49 | 0.320 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2421 | 0.320 |
Why?
| | Databases, Factual | 2 | 2025 | 1261 | 0.320 |
Why?
| | Fluconazole | 3 | 2023 | 18 | 0.310 |
Why?
| | Young Adult | 9 | 2024 | 12438 | 0.310 |
Why?
| | Biomarkers, Tumor | 1 | 2015 | 1159 | 0.310 |
Why?
| | Aged, 80 and over | 5 | 2024 | 7052 | 0.300 |
Why?
| | Arthritis, Infectious | 1 | 2009 | 58 | 0.300 |
Why?
| | Pulmonary Emphysema | 1 | 2011 | 275 | 0.300 |
Why?
| | Presenilin-1 | 1 | 2008 | 31 | 0.290 |
Why?
| | Fatal Outcome | 2 | 2019 | 300 | 0.290 |
Why?
| | Immunoglobulin G | 3 | 2023 | 851 | 0.290 |
Why?
| | Engineering | 1 | 2018 | 25 | 0.290 |
Why?
| | Staphylococcal Infections | 3 | 2023 | 391 | 0.280 |
Why?
| | Social Responsibility | 1 | 2018 | 47 | 0.280 |
Why?
| | Echinocandins | 2 | 2023 | 7 | 0.270 |
Why?
| | Mycobacterium | 2 | 2018 | 106 | 0.270 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1559 | 0.260 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2018 | 87 | 0.260 |
Why?
| | Public Health | 3 | 2020 | 484 | 0.260 |
Why?
| | Antiviral Agents | 1 | 2012 | 719 | 0.250 |
Why?
| | Attitude | 1 | 2018 | 254 | 0.250 |
Why?
| | HIV | 2 | 2018 | 227 | 0.250 |
Why?
| | Clinical Trials as Topic | 2 | 2020 | 1001 | 0.250 |
Why?
| | Sepsis | 2 | 2022 | 576 | 0.250 |
Why?
| | Electrocardiography | 2 | 2019 | 612 | 0.240 |
Why?
| | Propensity Score | 2 | 2023 | 266 | 0.240 |
Why?
| | Shock, Septic | 2 | 2021 | 209 | 0.240 |
Why?
| | Acute Kidney Injury | 1 | 2013 | 789 | 0.240 |
Why?
| | Clarithromycin | 1 | 2025 | 28 | 0.240 |
Why?
| | Erythromycin | 1 | 2025 | 24 | 0.240 |
Why?
| | Candida tropicalis | 1 | 2024 | 4 | 0.240 |
Why?
| | Polymorphism, Genetic | 1 | 2008 | 636 | 0.230 |
Why?
| | Cross Reactions | 1 | 2025 | 132 | 0.230 |
Why?
| | Insect Bites and Stings | 1 | 2024 | 11 | 0.230 |
Why?
| | Strongyloides stercoralis | 1 | 2024 | 2 | 0.230 |
Why?
| | Azithromycin | 1 | 2025 | 93 | 0.220 |
Why?
| | Colorado | 3 | 2020 | 4403 | 0.220 |
Why?
| | Teicoplanin | 2 | 2023 | 15 | 0.220 |
Why?
| | Peru | 2 | 2024 | 54 | 0.210 |
Why?
| | World Health Organization | 2 | 2021 | 110 | 0.210 |
Why?
| | Anaphylaxis | 1 | 2025 | 99 | 0.210 |
Why?
| | Toxoplasmosis | 1 | 2023 | 37 | 0.210 |
Why?
| | Toxoplasma | 1 | 2023 | 39 | 0.210 |
Why?
| | Meningoencephalitis | 1 | 2023 | 25 | 0.210 |
Why?
| | Alanine | 1 | 2024 | 143 | 0.210 |
Why?
| | Voriconazole | 1 | 2023 | 20 | 0.210 |
Why?
| | Rabies | 1 | 2022 | 1 | 0.200 |
Why?
| | Rabies Vaccines | 1 | 2022 | 2 | 0.200 |
Why?
| | Predictive Value of Tests | 2 | 2019 | 1950 | 0.200 |
Why?
| | Glycopeptides | 1 | 2023 | 43 | 0.200 |
Why?
| | Antiparasitic Agents | 1 | 2022 | 3 | 0.200 |
Why?
| | Pyridones | 1 | 2024 | 158 | 0.200 |
Why?
| | Students | 1 | 2018 | 581 | 0.200 |
Why?
| | Tenofovir | 1 | 2024 | 232 | 0.200 |
Why?
| | Kaplan-Meier Estimate | 1 | 2024 | 850 | 0.200 |
Why?
| | Tomography, X-Ray Computed | 4 | 2019 | 2503 | 0.200 |
Why?
| | Dog Diseases | 1 | 2022 | 51 | 0.190 |
Why?
| | Americas | 1 | 2022 | 24 | 0.190 |
Why?
| | Prognosis | 3 | 2022 | 3772 | 0.190 |
Why?
| | Drug Therapy, Combination | 2 | 2018 | 1037 | 0.190 |
Why?
| | Pregnancy | 4 | 2024 | 6412 | 0.190 |
Why?
| | Alzheimer Disease | 1 | 2008 | 516 | 0.190 |
Why?
| | Sexually Transmitted Diseases | 1 | 2024 | 150 | 0.190 |
Why?
| | Disease Notification | 1 | 2022 | 13 | 0.190 |
Why?
| | Italy | 1 | 2022 | 98 | 0.190 |
Why?
| | Travel Medicine | 2 | 2020 | 5 | 0.190 |
Why?
| | Staphylococcal Skin Infections | 2 | 2012 | 35 | 0.190 |
Why?
| | Leprosy | 1 | 2021 | 22 | 0.180 |
Why?
| | Proportional Hazards Models | 1 | 2024 | 1196 | 0.180 |
Why?
| | Rural Population | 2 | 2022 | 520 | 0.180 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2023 | 228 | 0.180 |
Why?
| | Population Dynamics | 1 | 2022 | 138 | 0.180 |
Why?
| | Leishmania guyanensis | 1 | 2020 | 1 | 0.170 |
Why?
| | Case-Control Studies | 3 | 2018 | 3383 | 0.170 |
Why?
| | Antiprotozoal Agents | 1 | 2020 | 13 | 0.170 |
Why?
| | Phosphorylcholine | 1 | 2020 | 18 | 0.170 |
Why?
| | Personal Protective Equipment | 1 | 2021 | 50 | 0.170 |
Why?
| | Leishmaniasis, Cutaneous | 1 | 2020 | 10 | 0.170 |
Why?
| | Pericarditis | 1 | 2020 | 11 | 0.170 |
Why?
| | Weight Gain | 1 | 2024 | 510 | 0.170 |
Why?
| | Anti-Inflammatory Agents | 1 | 2024 | 481 | 0.170 |
Why?
| | Receptors, Interleukin-6 | 1 | 2020 | 37 | 0.170 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2022 | 1203 | 0.170 |
Why?
| | Communicable Diseases, Emerging | 1 | 2020 | 32 | 0.170 |
Why?
| | Africa | 1 | 2020 | 99 | 0.170 |
Why?
| | Developing Countries | 1 | 2022 | 282 | 0.160 |
Why?
| | Late Onset Disorders | 1 | 2019 | 2 | 0.160 |
Why?
| | Immunization, Secondary | 1 | 2020 | 87 | 0.160 |
Why?
| | Bolivia | 1 | 2019 | 63 | 0.160 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2020 | 64 | 0.160 |
Why?
| | Proteinuria | 1 | 2020 | 91 | 0.160 |
Why?
| | Infection Control | 1 | 2021 | 143 | 0.160 |
Why?
| | Genetic Predisposition to Disease | 1 | 2008 | 2271 | 0.160 |
Why?
| | Sexual and Gender Minorities | 1 | 2022 | 196 | 0.160 |
Why?
| | Invasive Fungal Infections | 1 | 2019 | 10 | 0.160 |
Why?
| | Prospective Studies | 4 | 2023 | 7150 | 0.160 |
Why?
| | Medical Errors | 1 | 2020 | 107 | 0.150 |
Why?
| | Amphotericin B | 1 | 2019 | 30 | 0.150 |
Why?
| | Immunosuppressive Agents | 1 | 2024 | 858 | 0.150 |
Why?
| | Cryptococcus gattii | 1 | 2018 | 1 | 0.150 |
Why?
| | Acute Disease | 2 | 2012 | 975 | 0.150 |
Why?
| | Vulnerable Populations | 1 | 2020 | 155 | 0.150 |
Why?
| | Observational Studies as Topic | 1 | 2019 | 110 | 0.150 |
Why?
| | Dermatitis | 1 | 2018 | 19 | 0.150 |
Why?
| | Speech Disorders | 1 | 2018 | 34 | 0.150 |
Why?
| | Echocardiography | 2 | 2020 | 635 | 0.150 |
Why?
| | Computed Tomography Angiography | 1 | 2019 | 115 | 0.150 |
Why?
| | Africa, Western | 1 | 2018 | 17 | 0.150 |
Why?
| | Stroke Volume | 1 | 2021 | 593 | 0.150 |
Why?
| | Emigrants and Immigrants | 1 | 2020 | 122 | 0.150 |
Why?
| | Antibodies, Neutralizing | 1 | 2020 | 265 | 0.150 |
Why?
| | Administration, Intravenous | 1 | 2019 | 142 | 0.150 |
Why?
| | Sex Factors | 1 | 2024 | 1966 | 0.150 |
Why?
| | Neoplasms | 1 | 2013 | 2450 | 0.150 |
Why?
| | Raw Foods | 1 | 2018 | 2 | 0.150 |
Why?
| | California | 1 | 2019 | 393 | 0.150 |
Why?
| | Time Factors | 2 | 2019 | 6530 | 0.150 |
Why?
| | Ventricular Function, Left | 1 | 2021 | 529 | 0.140 |
Why?
| | Itraconazole | 1 | 2017 | 6 | 0.140 |
Why?
| | Administration, Oral | 2 | 2020 | 783 | 0.140 |
Why?
| | Prisoners | 1 | 2020 | 141 | 0.140 |
Why?
| | Respiration, Artificial | 1 | 2022 | 615 | 0.140 |
Why?
| | Food Microbiology | 1 | 2018 | 61 | 0.140 |
Why?
| | Georgia | 1 | 2017 | 80 | 0.140 |
Why?
| | Arrhythmias, Cardiac | 1 | 2020 | 321 | 0.140 |
Why?
| | Hyponatremia | 1 | 2018 | 39 | 0.140 |
Why?
| | Longitudinal Studies | 2 | 2019 | 2724 | 0.140 |
Why?
| | Cytokines | 2 | 2022 | 2018 | 0.140 |
Why?
| | Disability Evaluation | 1 | 2019 | 283 | 0.130 |
Why?
| | Patient Safety | 1 | 2020 | 287 | 0.130 |
Why?
| | Research Design | 2 | 2021 | 1043 | 0.130 |
Why?
| | Farmers | 1 | 2017 | 67 | 0.130 |
Why?
| | Antibodies, Viral | 1 | 2020 | 602 | 0.130 |
Why?
| | Mebendazole | 1 | 2016 | 2 | 0.130 |
Why?
| | Strongyloides | 1 | 2016 | 2 | 0.130 |
Why?
| | Trichuris | 1 | 2016 | 3 | 0.130 |
Why?
| | Arachis | 1 | 2017 | 109 | 0.130 |
Why?
| | Albendazole | 1 | 2016 | 5 | 0.130 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 244 | 0.130 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 761 | 0.130 |
Why?
| | Ivermectin | 1 | 2016 | 13 | 0.130 |
Why?
| | Pharmacists | 1 | 2019 | 247 | 0.130 |
Why?
| | Interleukin-6 | 1 | 2020 | 724 | 0.130 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1211 | 0.130 |
Why?
| | Hematocrit | 1 | 2016 | 92 | 0.130 |
Why?
| | Evidence-Based Medicine | 1 | 2020 | 715 | 0.130 |
Why?
| | Hospitals, University | 1 | 2016 | 179 | 0.120 |
Why?
| | Vaccination | 2 | 2022 | 1348 | 0.120 |
Why?
| | Praziquantel | 1 | 2015 | 5 | 0.120 |
Why?
| | Brain | 1 | 2008 | 2675 | 0.120 |
Why?
| | Anthelmintics | 1 | 2015 | 10 | 0.120 |
Why?
| | Clone Cells | 1 | 2016 | 262 | 0.120 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1422 | 0.120 |
Why?
| | Disease Outbreaks | 3 | 2023 | 349 | 0.120 |
Why?
| | Mental Disorders | 1 | 2023 | 1026 | 0.120 |
Why?
| | Genotype | 2 | 2012 | 1827 | 0.120 |
Why?
| | Recurrence | 1 | 2018 | 1011 | 0.120 |
Why?
| | Lipids | 1 | 2019 | 614 | 0.120 |
Why?
| | Health Care Costs | 1 | 2018 | 366 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2018 | 478 | 0.120 |
Why?
| | Migraine Disorders | 1 | 2016 | 101 | 0.110 |
Why?
| | Herpesvirus 4, Human | 1 | 2015 | 157 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2015 | 128 | 0.110 |
Why?
| | Hearing Loss | 1 | 2018 | 209 | 0.110 |
Why?
| | Frontal Lobe | 1 | 2015 | 154 | 0.110 |
Why?
| | Biopsy | 2 | 2020 | 1087 | 0.110 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 535 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1491 | 0.110 |
Why?
| | Heart Transplantation | 1 | 2020 | 722 | 0.110 |
Why?
| | Hemoglobins | 1 | 2016 | 337 | 0.110 |
Why?
| | Delivery of Health Care | 1 | 2021 | 896 | 0.110 |
Why?
| | Health Status Disparities | 3 | 2020 | 256 | 0.100 |
Why?
| | Parasite Load | 1 | 2013 | 8 | 0.100 |
Why?
| | Mycoplasma hominis | 1 | 2012 | 4 | 0.100 |
Why?
| | Mycoplasma Infections | 1 | 2012 | 15 | 0.100 |
Why?
| | APACHE | 1 | 2013 | 65 | 0.100 |
Why?
| | Intestines | 1 | 2016 | 350 | 0.100 |
Why?
| | Klebsiella Infections | 1 | 2013 | 25 | 0.100 |
Why?
| | Platelet Count | 1 | 2013 | 82 | 0.100 |
Why?
| | Disease Progression | 2 | 2012 | 2628 | 0.100 |
Why?
| | Logistic Models | 1 | 2018 | 1983 | 0.100 |
Why?
| | Comorbidity | 2 | 2022 | 1548 | 0.100 |
Why?
| | Molecular Typing | 1 | 2012 | 21 | 0.100 |
Why?
| | Clindamycin | 1 | 2012 | 13 | 0.100 |
Why?
| | Feces | 1 | 2015 | 442 | 0.100 |
Why?
| | Anti-HIV Agents | 2 | 2024 | 757 | 0.100 |
Why?
| | Syncope | 1 | 2013 | 51 | 0.100 |
Why?
| | Serratia Infections | 1 | 2012 | 7 | 0.100 |
Why?
| | Child | 6 | 2023 | 20932 | 0.100 |
Why?
| | Serratia marcescens | 1 | 2012 | 18 | 0.100 |
Why?
| | Linkage Disequilibrium | 1 | 2013 | 257 | 0.100 |
Why?
| | Central America | 2 | 2023 | 21 | 0.100 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2013 | 79 | 0.100 |
Why?
| | Disease Eradication | 2 | 2022 | 4 | 0.090 |
Why?
| | Mice, Inbred BALB C | 1 | 2015 | 1248 | 0.090 |
Why?
| | Thoracic Vertebrae | 1 | 2012 | 73 | 0.090 |
Why?
| | Hedgehog Proteins | 1 | 2013 | 188 | 0.090 |
Why?
| | Viral Load | 2 | 2024 | 449 | 0.090 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2015 | 502 | 0.090 |
Why?
| | Blister | 1 | 2011 | 41 | 0.090 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2011 | 38 | 0.090 |
Why?
| | Microscopy | 1 | 2013 | 140 | 0.090 |
Why?
| | Drug Resistance, Bacterial | 1 | 2012 | 175 | 0.090 |
Why?
| | Drug Resistance, Viral | 1 | 2012 | 110 | 0.090 |
Why?
| | Poliovirus Vaccine, Oral | 2 | 2022 | 25 | 0.090 |
Why?
| | Soft Tissue Infections | 1 | 2011 | 36 | 0.090 |
Why?
| | Venezuela | 2 | 2021 | 7 | 0.090 |
Why?
| | Prevalence | 1 | 2018 | 2561 | 0.090 |
Why?
| | Spinal Fractures | 1 | 2012 | 84 | 0.090 |
Why?
| | Myocardium | 1 | 2016 | 981 | 0.090 |
Why?
| | Coinfection | 1 | 2012 | 131 | 0.090 |
Why?
| | HIV Seropositivity | 1 | 2011 | 120 | 0.090 |
Why?
| | Cross Infection | 1 | 2013 | 219 | 0.090 |
Why?
| | Urinary Tract Infections | 1 | 2012 | 151 | 0.090 |
Why?
| | Gene Expression | 1 | 2015 | 1461 | 0.080 |
Why?
| | Cross-Sectional Studies | 2 | 2019 | 5078 | 0.080 |
Why?
| | Cohort Studies | 3 | 2022 | 5423 | 0.080 |
Why?
| | Community-Acquired Infections | 1 | 2012 | 160 | 0.080 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2013 | 245 | 0.080 |
Why?
| | Penicillanic Acid | 1 | 2009 | 4 | 0.080 |
Why?
| | Piperacillin | 1 | 2009 | 8 | 0.080 |
Why?
| | Mice | 3 | 2023 | 16973 | 0.080 |
Why?
| | Bacterial Typing Techniques | 1 | 2009 | 43 | 0.080 |
Why?
| | Surgical Wound Infection | 1 | 2012 | 282 | 0.080 |
Why?
| | Debridement | 1 | 2009 | 83 | 0.080 |
Why?
| | Spinal Cord Injuries | 1 | 2012 | 195 | 0.080 |
Why?
| | Anti-Infective Agents | 1 | 2011 | 249 | 0.080 |
Why?
| | Hypertension | 1 | 2018 | 1235 | 0.080 |
Why?
| | Infusions, Intravenous | 1 | 2009 | 402 | 0.070 |
Why?
| | Needs Assessment | 2 | 2021 | 355 | 0.070 |
Why?
| | Mortality | 2 | 2021 | 306 | 0.070 |
Why?
| | Genes, Dominant | 1 | 2008 | 94 | 0.070 |
Why?
| | Socialization | 1 | 2018 | 25 | 0.070 |
Why?
| | Chromosome Disorders | 1 | 2008 | 40 | 0.070 |
Why?
| | Global Health | 2 | 2020 | 328 | 0.070 |
Why?
| | Point Mutation | 1 | 2008 | 224 | 0.070 |
Why?
| | Genetic Markers | 1 | 2008 | 334 | 0.070 |
Why?
| | Amino Acid Substitution | 1 | 2008 | 284 | 0.070 |
Why?
| | DNA Mutational Analysis | 1 | 2008 | 378 | 0.070 |
Why?
| | Pedigree | 1 | 2008 | 482 | 0.070 |
Why?
| | Gene Frequency | 1 | 2008 | 500 | 0.070 |
Why?
| | Intensive Care Units | 2 | 2023 | 737 | 0.070 |
Why?
| | Chronic Disease | 1 | 2012 | 1722 | 0.060 |
Why?
| | Wounds and Injuries | 1 | 2012 | 711 | 0.060 |
Why?
| | Kidney Failure, Chronic | 1 | 2011 | 546 | 0.060 |
Why?
| | Amyloid beta-Peptides | 1 | 2008 | 211 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2062 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2544 | 0.060 |
Why?
| | Adenocarcinoma | 1 | 2012 | 889 | 0.060 |
Why?
| | Genetic Testing | 1 | 2008 | 422 | 0.060 |
Why?
| | Interviews as Topic | 1 | 2018 | 707 | 0.060 |
Why?
| | Registries | 1 | 2013 | 1902 | 0.060 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 995 | 0.060 |
Why?
| | Antivenins | 1 | 2024 | 35 | 0.060 |
Why?
| | Moths | 1 | 2024 | 39 | 0.060 |
Why?
| | Mice, Inbred C57BL | 1 | 2015 | 5468 | 0.060 |
Why?
| | Aminobutyrates | 1 | 2024 | 33 | 0.060 |
Why?
| | Drug Substitution | 1 | 2024 | 51 | 0.050 |
Why?
| | Peptide Fragments | 1 | 2008 | 695 | 0.050 |
Why?
| | Acetazolamide | 1 | 2023 | 24 | 0.050 |
Why?
| | Antibodies, Protozoan | 1 | 2023 | 32 | 0.050 |
Why?
| | Human Rights | 1 | 2023 | 18 | 0.050 |
Why?
| | Seroepidemiologic Studies | 1 | 2023 | 157 | 0.050 |
Why?
| | Adolescent | 4 | 2023 | 20409 | 0.050 |
Why?
| | HIV Integrase Inhibitors | 1 | 2024 | 69 | 0.050 |
Why?
| | Panama | 1 | 2022 | 12 | 0.050 |
Why?
| | Yellow fever virus | 1 | 2022 | 3 | 0.050 |
Why?
| | Medicine, Traditional | 1 | 2022 | 22 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 148 | 0.050 |
Why?
| | Monkeypox virus | 1 | 2022 | 13 | 0.050 |
Why?
| | Standard of Care | 1 | 2023 | 71 | 0.050 |
Why?
| | Cell Line | 1 | 2008 | 2774 | 0.050 |
Why?
| | CD4 Lymphocyte Count | 1 | 2023 | 267 | 0.050 |
Why?
| | Poliovirus Vaccine, Inactivated | 1 | 2022 | 28 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2023 | 276 | 0.050 |
Why?
| | Vancomycin | 1 | 2023 | 78 | 0.050 |
Why?
| | Adenine | 1 | 2024 | 257 | 0.050 |
Why?
| | Mexico | 1 | 2022 | 191 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2012 | 4073 | 0.050 |
Why?
| | Cameroon | 1 | 2021 | 8 | 0.050 |
Why?
| | Cuba | 1 | 2021 | 12 | 0.050 |
Why?
| | Mycobacterium leprae | 1 | 2021 | 8 | 0.050 |
Why?
| | Microbial Sensitivity Tests | 1 | 2023 | 349 | 0.050 |
Why?
| | Contact Tracing | 1 | 2021 | 24 | 0.050 |
Why?
| | Healthy Volunteers | 1 | 2022 | 199 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 2044 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2019 | 5429 | 0.050 |
Why?
| | Dogs | 1 | 2022 | 385 | 0.050 |
Why?
| | Curriculum | 1 | 2018 | 922 | 0.050 |
Why?
| | Homosexuality, Male | 1 | 2022 | 176 | 0.050 |
Why?
| | Minority Health | 1 | 2021 | 20 | 0.040 |
Why?
| | Cardiovascular Infections | 1 | 2020 | 2 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 170 | 0.040 |
Why?
| | Pericardiocentesis | 1 | 2020 | 10 | 0.040 |
Why?
| | History, 17th Century | 1 | 2020 | 14 | 0.040 |
Why?
| | Minority Groups | 1 | 2022 | 250 | 0.040 |
Why?
| | Bone Diseases, Infectious | 1 | 2020 | 8 | 0.040 |
Why?
| | Inflammation | 2 | 2022 | 2741 | 0.040 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2024 | 367 | 0.040 |
Why?
| | Social Justice | 1 | 2021 | 76 | 0.040 |
Why?
| | Network Meta-Analysis | 1 | 2020 | 9 | 0.040 |
Why?
| | Hemorrhage | 1 | 2024 | 680 | 0.040 |
Why?
| | Crowding | 1 | 2020 | 35 | 0.040 |
Why?
| | Communicable Disease Control | 1 | 2020 | 75 | 0.040 |
Why?
| | Outpatients | 1 | 2023 | 375 | 0.040 |
Why?
| | Policy Making | 1 | 2020 | 88 | 0.040 |
Why?
| | Brazil | 1 | 2020 | 154 | 0.040 |
Why?
| | Catheter-Related Infections | 1 | 2020 | 72 | 0.040 |
Why?
| | Signal Transduction | 1 | 2013 | 4916 | 0.040 |
Why?
| | History, 21st Century | 1 | 2020 | 186 | 0.040 |
Why?
| | Frail Elderly | 1 | 2020 | 120 | 0.040 |
Why?
| | History, 20th Century | 1 | 2020 | 295 | 0.040 |
Why?
| | Cough | 1 | 2020 | 117 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2023 | 436 | 0.040 |
Why?
| | Southeastern United States | 1 | 2018 | 31 | 0.040 |
Why?
| | Skilled Nursing Facilities | 1 | 2020 | 130 | 0.040 |
Why?
| | Quality Assurance, Health Care | 1 | 2021 | 316 | 0.040 |
Why?
| | Drug Compounding | 1 | 2019 | 97 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2022 | 226 | 0.040 |
Why?
| | Nursing Homes | 1 | 2020 | 159 | 0.040 |
Why?
| | Immunization Schedule | 1 | 2020 | 197 | 0.040 |
Why?
| | HIV-1 | 1 | 2024 | 839 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2020 | 229 | 0.040 |
Why?
| | Risk | 1 | 2020 | 857 | 0.030 |
Why?
| | Residence Characteristics | 1 | 2020 | 331 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2020 | 1031 | 0.030 |
Why?
| | Critical Illness | 1 | 2023 | 758 | 0.030 |
Why?
| | Organ Transplantation | 1 | 2020 | 228 | 0.030 |
Why?
| | Urban Population | 1 | 2020 | 442 | 0.030 |
Why?
| | Hospitals | 1 | 2022 | 649 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2020 | 548 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2020 | 302 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 755 | 0.030 |
Why?
| | Mass Screening | 1 | 2022 | 1186 | 0.030 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2011 | 3622 | 0.030 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2012 | 22 | 0.020 |
Why?
| | Molecular Epidemiology | 1 | 2012 | 63 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3255 | 0.020 |
Why?
| | Infant | 1 | 2021 | 9005 | 0.020 |
Why?
| | Lung | 1 | 2020 | 3928 | 0.020 |
Why?
| | Child, Preschool | 1 | 2021 | 10499 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2013 | 0.020 |
Why?
|
|
Henao Martinez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|